Eyenovia enrolling broad patient population in MicroProst phase 3 trial

Eyenovia will include a broad patient population, including patients with chronic angle closure glaucoma, open-angle glaucoma and ocular hypertension, in a phase 3 trial of MicroProst, according to a press release.

MicroProst (microdose latanoprost with Optejet delivery) uses Eyenovia’s piezo-print delivery technology to deliver microdoses of IOP-lowering medications.

“If approved, MicroProst could have one of the widest indications of commercially available IOP-lowering therapies, as well as represent the first FDA-approved drug specifically indicated for chronic angle closure glaucoma,” Sean Ianchulev, MD, MPH, Eyenovia CEO and chief medical officer, said in the release. “Based on the results of our earlier phase 2 trial for IOP lowering, we believe that MicroProst may achieve similar clinical efficacy with improved tolerability vs. latanoprost administered in drop form, which can overdose the eye with potentially harmful preservatives and active ingredient.”

Eyenovia will include a broad patient population, including patients with chronic angle closure glaucoma, open-angle glaucoma and ocular hypertension, in a phase 3 trial of MicroProst, according to a press release.

MicroProst (microdose latanoprost with Optejet delivery) uses Eyenovia’s piezo-print delivery technology to deliver microdoses of IOP-lowering medications.

“If approved, MicroProst could have one of the widest indications of commercially available IOP-lowering therapies, as well as represent the first FDA-approved drug specifically indicated for chronic angle closure glaucoma,” Sean Ianchulev, MD, MPH, Eyenovia CEO and chief medical officer, said in the release. “Based on the results of our earlier phase 2 trial for IOP lowering, we believe that MicroProst may achieve similar clinical efficacy with improved tolerability vs. latanoprost administered in drop form, which can overdose the eye with potentially harmful preservatives and active ingredient.”